Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins

Blood

Volumn 91, Issue 5, 1998, Pages 1820-1827

  Spyridonidis, A ^b   Schmidt, M ^b   Bernhardt, W ^b   Papadimitriou, A ^b   Azemar, M ^b   Wels, W ^b   Groner, B ^b   Henschler, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW PURGING; BREAST CARCINOMA; CARCINOMA CELL; CELL GROWTH; CELL SUBPOPULATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LEUKAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; STEM CELL; TARGET CELL;

EID: 0032031512     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.5.1820     Document Type: Article

References (36)

1. Kessinger A, Armitage JO: The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 77:211, 1991
2. Peters WP: High dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer, in DeVita VT, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1995, p 215
3. Bezwoda WR, Seymour I, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483, 1995
4. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Jr, Anderson WF, Ihle JN: Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85, 1993
5. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation for CML. Blood 83:3068, 1994
6. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380, 1994
7. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Winter C, Akard L, Jansen J, Copelan E, Meagher RC, Herzig RH, Klumpp RT, Kahn DG, Warner NE: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605, 1993
8. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636, 1994
9. Sharp JG, Mann SL, Murphy B, Weekes C: Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: A review. J Hematother 4:141, 1995
10. Kessinger A, Reed E, Vaughan W, Sharp J: Clinical outcome of patients with breast cancer and gynecological epithelial tumors undergoing high dose therapy and peripheral blood stem cell transplantation with or without minimally contaminated apheresis harvests. Proc Am Soc Clin Oncol 12:74, 1993 (abstr)
11. Brockstein BE, Ross AA, Moss TJ, Kahn DG, Hollingsworth K, Williams SF: Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy (HDC). J Hematother 5:617, 1996
12. Fields KK, Elfenbein GJ, Perkins JB, Moscinski LC: High dose versus standard dose chemotherapy for the treatment of breast cancer. Ann NY Acad Sci 770:288, 1995
13. Berenson RJ, Shpall EJ, Franklin WA, Jones RB, Bearman SI, Purdy RH, Cagnoni P, Heimfeld S: Transplantation of CD34 positive marrow and/or peripheral blood progenitor cells into breast cancer patients following high dose chemotherapy. Bone Marrow Transplant 15:32, 1995 (abstr)
14. Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Bitter M, Claman HN, Stemmer SM, Purdy M, Myers SM, Hami L, Taffs S, Heimfeld S, Hallagan J, Berenson RJ: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12:28, 1994
15. Mapara MY, Körner IJ, Hildebrandt M, Bargou R, Krahl D, Reichardt P, Dörken B: Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 89:337, 1997
16. Emerson SG: Ex vivo expansion of hematopoietic progenitors and stem cells: The next generation of cellular therapeutics. Blood 87:3082, 1996
17. + cells and unseparated peripheral blood progenitor cells. Blood 80:1405, 1992
18. + progenitor cells by stem cell factor, interleukin-(IL)-1 beta, IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 81:2579, 1993
19. + peripheral blood progenitor cells. Blood 84:2898, 1994
20. Petzer AL, Hogge DE, Lansorp PM, Reid DS, Eaves CJ: Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 93:1470, 1996
21. + cells mediate hematopoietic recovery after high dose chemotherapy. N Engl J Med 333:283, 1995
22. + peripheral blood progenitor cells: Implications for the expansion of contaminating epithelial tumor cells. Blood 88:2707, 1996
23. Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverley PCL, Neville DM, Youle RJ: Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222:512, 1983
24. Filipovich A, Youle AJ, Neville DM, Vallera DA, Quinones RR, Kersey JH: Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease. Lancet 1:469, 1984
25. Myklebust AT, Godal A, Pharo A, Juell S, Fodstad O: Eradication of small cell lung cancer cells from human bone marrow with immunotoxins. Cancer Res 53:3784, 1993
26. Myklebust AT, Godal A, Juell S, Pharo A, Fodstad O: Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 54:209, 1994
27. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE: Selective inhibition of tumor cell growth by a recombinant single chain antibody toxin specific for the ErbB-2 receptor. Cancer Res 52:6310, 1992
28. Schmidt M, Vakalopoulou E, Schneider DW, Wels W: Construction and functional characterization of scFv(14E1)-ETA - A novel, highly potent antibody-toxin specific for the EGF receptor. Br J Cancer 75:1575, 1997
29. Ogata M, Fryling CM, Pastan I, Fitzgerald DJ: Cell-mediated cleavage of Psedomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem 267:25396, 1992
30. Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4:19, 1993
31. Tondini C, Pap SA, Hayes DF, Elias AD, Kufe DW: Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res 50:1170, 1990
32. O'Briant KC, Sphall EJ, Houston LL, Peters WP, Bast RC Jr: Elimination of clonogenic breast cancer cells from human bone marrow. Cancer 68:1272, 1991
33. Bjorn MJ, Manger R, Sivam G, Morgan AC Jr, Torok-Storb B: Selective elimination of breast cancer cells from human bone marrow using an antibody-Pseudomonas exotoxin A conjugate. Cancer Res 50:5992, 1990
34. Coombes CR, Buckman R, Forrester AJ, Shepherd V, O'Hare MJ, Vincent M, Powles TJ, Neville AM: In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer. Cancer Res 46:4217, 1986
35. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmüller G: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419, 1993
36. Shpall EJ, Jones RB, Bast RC, Rosner GL, Vandermark R, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperburg M, Coniglio D, Peters WP: 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: A phase I trial. J Clin Oncol 9:85, 1991